BOSTON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines (PRAX), Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback